Denmark · Delayed Price · Currency is DKK ChemoMetec Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 3% to DKK 511 million, led by strong instrument sales, especially XcytoMatic and NC-203, while EBITDA margin rose to 55%. Guidance for FY 2026/2027 anticipates 7–13% revenue growth, driven by instrument replacements and automation, with continued investment in software and partnerships.
-
Revenue grew 8% year-over-year with strong XM platform adoption and improved margins. Upgraded guidance reflects broad customer interest, with larger XM orders expected by fiscal year-end. Strategic focus is on software and automation, supporting long-term profitability.
Fiscal Year 2025
-
Revenue, EBITDA, and cash flow increased year-over-year, with strong growth across all segments and a high gross margin. Guidance anticipates 10–14% sales growth, margin improvement, and major investments in automation and software, while macro and currency risks remain.